Research

AR1001 slowed Alzheimer’s decline in one trial group but not overall

AR1001 slowed decline by 31% in 604 patients not taking other Alzheimer’s drugs, but the overall trial result was not statistically significant.

Reported by 2 outlets Wednesday, November 18, 2026

A caregiver reading a book with an older woman
Photo: Public domain

AR1001, a pill in the same family of medicines as Viagra, showed mixed results in people with early Alzheimer’s disease in the phase III POLARIS-AD trial, MedPage Today reported. The trial included 1,535 patients overall. At 52 weeks, the difference versus placebo in the overall group was -0.11 points on a measure of cognitive and functional impairment, which was not statistically significant (P=0.4015).

Among 604 patients not taking an acetylcholinesterase inhibitor or memantine at baseline, the treatment difference versus placebo was -0.44 points (P=0.0266), representing a 31% slowing of decline, MedPage Today reported. Diarrhea, falls and dizziness were the most frequent adverse events. The Guardian reported that experts called for further trials and said the drug would need regulatory review before it could be prescribed for Alzheimer’s.

Reporting on this story

More top stories

This Week in Medicine

The week in medicine, in five minutes

The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.

Free. No spam. Unsubscribe anytime.